Research and clinical diagnostics company Bio-Rad Laboratories (NYSE:BIO) announced that it has appointed Dara Grantham Wright as its executive VP and president of the clinical diagnostics group in a move made effective on Jan. 1.
Grantham Wright is taking over for John Hertia, who retired from the position on Dec. 31, 2019. Her responsibilities include providing global leadership and managing the overall strategy and business direction for Bio-Rad’s clinical diagnostic group.
The industry veteran most recently served as VP & GM of the biosciences division of the life science solutions group, focusing on protein and cell analysis at Thermo Fisher Scientific‘s (NYSE:TMO). Grantham Wright also held the role of senior VP & GM of the e-bioscience business unit at Affymetrix before working at Thermo Fisher Scientific.
“We are pleased to have Dara join Bio-Rad and believe she will make an excellent addition to our team,” Bio-Rad EVP & COO Andrew Last said in a news release. “Dara brings a wealth of experience, business acumen and a proven track record of success that make her the ideal person to lead our clinical diagnostics group. We would also like to thank John for his many years of valuable contributions to the growth and success of Bio-Rad, and we wish him the best in his retirement.”